This is perhaps at the heart of what makes him a literary phenomenon. It is almost as if you enter the landscape of my mind.” “I blend in memoir, history, personal history, deep history, the individual histories of my patients, and it all goes together. The Song of The Cell, like his other works, has the sweep of an epic and the pulsating urgency of a thriller. IIT Bombay and Tata Memorial are also doing similar trials theirs is in phase one, Immuneel is in phase two. Immuneel Therapeutics, the Bengaluru-based company that Mukherjee and Biocon chief Kiran Mazumdar Shaw started, is working towards a treatment that will cost far less than treatments in the US. “It is a process that can be highly effective in curing patients, but it is also very dangerous.” “A CAR T cell is a T cell that has been weaponised against cancer,” he says. His laboratory, which has a reputation for cancer research, is responsible for starting one of India’s first clinical trials of T cell therapy. Book aside, in December, he flies to Bengaluru to assess the results of a CAR (chimeric antigen receptor) T cell trial for cancer. The next two months are big for Mukherjee, for his various identities of oncologist, scientist, writer and now entrepreneur. Its arrival in stores is very much a worldwide publishing event. It is his fourth book, the earlier ones being The Emperor of All Maladies: A Biography of Cancer (which won him a Pulitzer), The Laws of Medicine: Field Notes from an Uncertain Science and The Gene: An Intimate History. Mukherjee is in his loft in New York, making a sandwich and promoting his new book The Song of The Cell: An Exploration of Medicine and The New Human. In contrast to his books, where the reader gets a ringside view of the messiness of medicine, his life is very much Instagram worthy.
0 kommentar(er)
